Guillermo Garcia-Manero, MD
Associate Editor
Dr. Garcia-Manero is Chief of the Section of Myelodysplastic Syndromes, Deputy Chair of Translational Research, and a Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.
Articles by Guillermo Garcia-Manero, MD
In this roundtable segment, the panel discussed imetelstat for the treatment of lower-risk MDS.
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss which patients with MDS should be treated with luspatercept.
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss dosing considerations for luspatercept for lower-risk MDS.
The panel discussed the four COMMANDS trial abstracts on luspatercept for lower-risk MDS presented at EHA 2024.
In the next roundtable segment, the panel discusses risk stratifying patients with the IPSS-R and IPSS-M.
An expert panel discusses how to measure the MDS patient experience and whether it’s time for new endpoints in MDS.
Dr. Garcia-Manero discusses the latest updates from the COMMANDS trial.
A roundtable discussion, moderated by Guillermo Garcia-Manero, MD, discussed the current state of MDS treatment.
Dr. Garcia-Manero discussed luspatercept, a first-in-class drug for patients with low-risk MDS and anemia.
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, at the George R. Brown Convention Center in Houston, Texas.
Dr. Garcia-Manero discussed the phase II ASTREON trial on myelodysplastic syndromes at the 2024 ASCO Annual Meeting.
Early detection and prevention are particularly important in leukemia, Dr. Garcia-Manero explained.
The panel discusses forward-looking thoughts for the treatment of low-risk myelodysplastic syndromes.
The panel talks about the use of transplant for patients with low-risk myelodysplastic syndromes.
The panel discusses other treatments undergoing research for MDS, including imetelstat and KER-050.
The panel shared their thoughts on real-world data of luspatercept presented at ASH 2023.
The panel addresses continued MDS research needs.
The panel discusses appropriate treatment selection based on patient mutation status and comorbidities.
The panel shares their thoughts on the full analysis of the COMMANDS study.
The panel discussed the current slate of treatment options for patients with low-risk MDS.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.